T1	Content 9 148	Rorer Group Inc. will report that third-quarter profit rose more than 15% from a year earlier, though the gain is wholly due to asset sales
T2	Source 150 215	Robert Cawthorn, chairman, president and chief executive officer,
T3	Cue 216 220	said
T4	Attribution 216 220	said
E1	Attribution:T4 Cue:T3 Source:T2 Content:T1
T5	Source 224 238	His projection
T6	Cue 239 248	indicates
T7	Content 249 387	profit in the latest quarter of more than $17.4 million, or 55 cents a share, compared with $15.2 million, or 48 cents a share, a year ago
T8	Attribution 239 248	indicates
E2	Attribution:T8 Content:T7 Cue:T6 Source:T5
T9	Source 391 403	Mr. Cawthorn
T10	Cue 404 424	said in an interview
T11	Content 425 502	that sales will show an increase from a year ago of "somewhat less than 10%."
T12	Attribution 404 424	said in an interview
E3	Attribution:T12 Content:T11 Cue:T10 Source:T9
T13	Source 710 722	Mr. Cawthorn
T14	Cue 723 727	said
T15	Content 728 806	the profit growth in the latest quarter was due to the sale of two Rorer drugs
T16	Attribution 723 727	said
E4	Attribution:T16 Content:T15 Cue:T14 Source:T13
T17	Source 958 960	He
T18	Cue 961 965	said
T19	Content 966 1072	Rorer sold the drugs for "nice prices" and will record a combined, pretax gain on the sales of $20 million
T20	Attribution 961 965	said
E5	Attribution:T20 Content:T19 Cue:T18 Source:T17
T21	Content 1076 1179	As the gain from the sales indicates, operating profit was "significantly" below the year-earlier level
T22	Source 1181 1193	Mr. Cawthorn
T23	Cue 1194 1198	said
T24	Source 1300 1302	He
T25	Cue 1303 1307	said
T26	Content 1308 1422	the company is still looking for "a strong fourth quarter in all areas -- sales, operating income and net income."
T27	Attribution 1194 1198	said
E6	Attribution:T27 Cue:T23 Source:T22 Content:T21
T28	Attribution 1303 1307	said
E7	Attribution:T28 Content:T26 Cue:T25 Source:T24
T29	Source 1425 1437	Mr. Cawthorn
T30	Cue 1438 1448	attributed
T31	Content 1449 1517;1598 1768	the decline in third-quarter operating profit to the stronger dollar to accelerated buying of Rorer products in the second quarter because of a then-pending July 1 price increase, and to higher marketing expenses for Rorer's Maalox antacid
T32	Attribution 1438 1448	attributed
E8	Attribution:T32 Content:T31 Cue:T30 Source:T29
T33	Source 1850 1852	He
T34	Cue 1853 1857	said
T35	Content 1858 1987	Rorer opted to sell Asilone and Thrombinar to raise revenue that would "kick start" its increased marketing efforts behind Maalox
T36	Attribution 1853 1857	said
E9	Attribution:T36 Content:T35 Cue:T34 Source:T33
T37	Content 2072 2111;2121 2212	"We had underfunded Maalox for a year," because the company was concentrating on research and development and promoting other drugs
T38	Source 2112 2114	he
T39	Cue 2115 2119	said
T40	Attribution 2115 2119	said
E10	Attribution:T40 Cue:T39 Source:T38 Content:T37
T41	Source 2216 2218	He
T42	Cue 2219 2223	said
T43	Content 2224 2367	Rorer will spend $15 million to $20 million more on Maalox advertising and promotion in the second half of 1989 than in the year-earlier period
T44	Attribution 2219 2223	said
E11	Attribution:T44 Content:T43 Cue:T42 Source:T41
T45	Content 2369 2436	A "big chunk" of that additional spending came in the third quarter
T46	Source 2438 2440	he
T47	Cue 2441 2445	said
T48	Attribution 2441 2445	said
E12	Attribution:T48 Cue:T47 Source:T46 Content:T45
